Sa1775 - A Novel Phase 1 Trial Design to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Top1288, a Narrow Spectrum Kinase Inhibitor, Delivered Topically to the Colon via Oral Administration